Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal

被引:0
|
作者
Herrera, Bobby Brooke [1 ,2 ,3 ,4 ,5 ]
Chaplin, Beth [5 ]
Mboup, Souleymane [6 ]
Abdullahi, Adam [7 ,8 ]
He, Michelle [5 ]
Fisher, Sydney M. [5 ]
Akanmu, Sulaimon [9 ]
Chang, Charlotte A. [5 ]
Hamel, Donald J. [5 ]
Gupta, Ravindra K. [7 ,8 ]
Kanki, Phyllis J. [5 ]
机构
[1] Rutgers State Univ, Rutgers Global Hlth Inst, New Brunswick, NJ USA
[2] Rutgers State Univ, Dept Med, Div Allergy Immunol & Infect Dis, New Brunswick, NJ USA
[3] Rutgers State Univ, Child Hlth Inst New Jersey, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[4] Mir Biosci Inc, Dunellen, NJ USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[6] Inst Rech Sante Surveillance Epidemiol & Format IR, Dakar, Senegal
[7] Cambridge Inst Therapeut Immunol & Infect Dis CITI, Cambridge, England
[8] Univ Cambridge, Dept Med, Cambridge, England
[9] Univ Lagos, Lagos Univ Teaching Hosp, Coll Med, Lagos, Nigeria
关键词
SARS-CoV-2; antibody; cellular responses; cross-reactivity; Senegal; VIRUS-INFECTION; RESILIENCE; TARGETS; HIV-2;
D O I
10.3389/fpubh.2025.1522733
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background The COVID-19 pandemic had a severe impact globally, yet African populations exhibited unexpectedly lower rates of severe disease and mortality. We investigated the potential role of pre-existing immunity in shaping the epidemiology of COVID-19 in Africa.Methods Plasma collected from Senegalese female sex workers prior to the COVID-19 pandemic was screened for SARS-CoV-2 and human coronavirus (hCoV) antibodies by virion immunoblots. For antibody-reactive plasma, paired peripheral blood mononuclear cells were stimulated by fusion proteins and IFN-gamma cellular responses were assessed via ELISPOT.Results We observed substantial levels of pre-existing cross-reactive immunity to SARS-CoV-2, stemming from prior exposure to seasonal hCoVs. Our antibody analysis revealed a 23.5% (47/200) seroprevalence rate against SARS-CoV-2 nucleocapsid (N). These samples were then probed for antibodies against hCoV spike (S) and/or N antigens; 85.1% (40/47), 70.2% (33/47), and 95.7% (45/47) were antibody reactive against hCoV-229E, hCoV-OC43, or hCoV-HKU1, respectively. Our analysis of cellular responses also demonstrated cross-reactivity to SARS-CoV-2 with 80.0% (36/45) and 82.2% (37/45) showing IFN-gamma responses against S and N, respectively. A unique pre-pandemic subject had cross-reactive SARS-CoV-2 S antibodies with detectable neutralization and cross-reactive cellular responses.Conclusion These findings suggest that prior hCoV exposure may induce cross-reactive adaptive immunity, potentially contributing to protection against COVID-19. Our study provides unique data on the dynamics of hCoV and SARS-CoV-2 immunity in Senegal and underscores the importance of understanding the role of pre-existing immunity in shaping COVID-19 outcomes globally.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
    Dowell, Alexander C.
    Butler, Megan S.
    Jinks, Elizabeth
    Tut, Gokhan
    Lancaster, Tara
    Sylla, Panagiota
    Begum, Jusnara
    Bruton, Rachel
    Pearce, Hayden
    Verma, Kriti
    Logan, Nicola
    Tyson, Grace
    Spalkova, Eliska
    Margielewska-Davies, Sandra
    Taylor, Graham S.
    Syrimi, Eleni
    Baawuah, Frances
    Beckmann, Joanne
    Okike, Ifeanyichukwu
    Ahmad, Shazaad
    Garstang, Joanna
    Brent, Andrew J.
    Brent, Bernadette
    Ireland, Georgina
    Aiano, Felicity
    Amin-Chowdhury, Zahin
    Jones, Samuel
    Borrow, Ray
    Linley, Ezra
    Wright, John
    Azad, Rafaq
    Waiblinger, Dagmar
    Davis, Chris
    Thomson, Emma
    Palmarini, Massimo
    Willett, Brian J.
    Barclay, Wendy S.
    Poh, John
    Amirthalingam, Gayatri
    Brown, Kevin E.
    Ramsay, Mary E.
    Zuo, Jianmin
    Moss, Paul
    Ladhani, Shamez
    NATURE IMMUNOLOGY, 2022, 23 (01) : 40 - +
  • [42] T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
    Ane Ogbe
    Barbara Kronsteiner
    Donal T. Skelly
    Matthew Pace
    Anthony Brown
    Emily Adland
    Kareena Adair
    Hossain Delowar Akhter
    Mohammad Ali
    Serat-E Ali
    Adrienn Angyal
    M. Azim Ansari
    Carolina V. Arancibia-Cárcamo
    Helen Brown
    Senthil Chinnakannan
    Christopher Conlon
    Catherine de Lara
    Thushan de Silva
    Christina Dold
    Tao Dong
    Timothy Donnison
    David Eyre
    Amy Flaxman
    Helen Fletcher
    Joshua Gardner
    James T. Grist
    Carl-Philipp Hackstein
    Kanoot Jaruthamsophon
    Katie Jeffery
    Teresa Lambe
    Lian Lee
    Wenqin Li
    Nicholas Lim
    Philippa C. Matthews
    Alexander J. Mentzer
    Shona C. Moore
    Dean J. Naisbitt
    Monday Ogese
    Graham Ogg
    Peter Openshaw
    Munir Pirmohamed
    Andrew J. Pollard
    Narayan Ramamurthy
    Patpong Rongkard
    Sarah Rowland-Jones
    Oliver Sampson
    Gavin Screaton
    Alessandro Sette
    Lizzie Stafford
    Craig Thompson
    Nature Communications, 12
  • [43] AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
    Chibwana, Marah G.
    Moyo-Gwete, Thandeka
    Kwatra, Gaurav
    Mandolo, Jonathan
    Hermanaus, Tandile
    Motlou, Thopisang
    Mzindle, Nonkululeko
    Ayres, Frances
    Chaponda, Mphatso
    Tembo, Godwin
    Mwenechanya, Percy
    Mitole, Ndaona
    Jassi, Chisomo
    Kamng'ona, Raphael
    Afran, Louise
    Mzinza, David
    Mwandumba, Henry C.
    Gordon, Stephen B.
    Jere, Khuzwayo
    Madhi, Shabir
    Moore, Penny L.
    Heyderman, Robert S.
    Jambo, Kondwani C.
    BMC MEDICINE, 2022, 20 (01)
  • [44] Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
    Alexander C. Dowell
    Megan S. Butler
    Elizabeth Jinks
    Gokhan Tut
    Tara Lancaster
    Panagiota Sylla
    Jusnara Begum
    Rachel Bruton
    Hayden Pearce
    Kriti Verma
    Nicola Logan
    Grace Tyson
    Eliska Spalkova
    Sandra Margielewska-Davies
    Graham S. Taylor
    Eleni Syrimi
    Frances Baawuah
    Joanne Beckmann
    Ifeanyichukwu O. Okike
    Shazaad Ahmad
    Joanna Garstang
    Andrew J. Brent
    Bernadette Brent
    Georgina Ireland
    Felicity Aiano
    Zahin Amin-Chowdhury
    Samuel Jones
    Ray Borrow
    Ezra Linley
    John Wright
    Rafaq Azad
    Dagmar Waiblinger
    Chris Davis
    Emma C. Thomson
    Massimo Palmarini
    Brian J. Willett
    Wendy S. Barclay
    John Poh
    Gayatri Amirthalingam
    Kevin E. Brown
    Mary E. Ramsay
    Jianmin Zuo
    Paul Moss
    Shamez Ladhani
    Nature Immunology, 2022, 23 : 40 - 49
  • [45] T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
    Ogbe, Ane
    Kronsteiner, Barbara
    Skelly, Donal T.
    Pace, Matthew
    Brown, Anthony
    Adland, Emily
    Adair, Kareena
    Akhter, Hossain Delowar
    Ali, Mohammad
    Ali, Serat-E
    Angyal, Adrienn
    Ansari, M. Azim
    Arancibia-Carcamo, Carolina V.
    Brown, Helen
    Chinnakannan, Senthil
    Conlon, Christopher
    de Lara, Catherine
    de Silva, Thushan
    Dold, Christina
    Dong, Tao
    Donnison, Timothy
    Eyre, David
    Flaxman, Amy
    Fletcher, Helen
    Gardner, Joshua
    Grist, James T.
    Hackstein, Carl-Philipp
    Jaruthamsophon, Kanoot
    Jeffery, Katie
    Lambe, Teresa
    Lee, Lian
    Li, Wenqin
    Lim, Nicholas
    Matthews, Philippa C.
    Mentzer, Alexander J.
    Moore, Shona C.
    Naisbitt, Dean J.
    Ogese, Monday
    Ogg, Graham
    Openshaw, Peter
    Pirmohamed, Munir
    Pollard, Andrew J.
    Ramamurthy, Narayan
    Rongkard, Patpong
    Rowland-Jones, Sarah
    Sampson, Oliver
    Screaton, Gavin
    Sette, Alessandro
    Stafford, Lizzie
    Thompson, Craig
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [46] AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
    Marah G. Chibwana
    Thandeka Moyo-Gwete
    Gaurav Kwatra
    Jonathan Mandolo
    Tandile Hermanaus
    Thopisang Motlou
    Nonkululeko Mzindle
    Frances Ayres
    Mphatso Chaponda
    Godwin Tembo
    Percy Mwenechanya
    Ndaona Mitole
    Chisomo Jassi
    Raphael Kamng’ona
    Louise Afran
    David Mzinza
    Henry C. Mwandumba
    Stephen B. Gordon
    Khuzwayo Jere
    Shabir Madhi
    Penny L. Moore
    Robert S. Heyderman
    Kondwani C. Jambo
    BMC Medicine, 20
  • [47] Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide
    Vanderheijden, Nathalie
    Stevaert, Annelies
    Xie, Jiexiong
    Ren, Xiaolei
    Barbezange, Cyril
    Noppen, Sam
    Desombere, Isabelle
    Verhasselt, Bruno
    Geldhof, Peter
    Vereecke, Nick
    Stroobants, Veerle
    Oh, Dayoung
    Vanhee, Merijn
    Naesens, Lieve M. J.
    Nauwynck, Hans J.
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [48] Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
    van Gils, Marit J.
    Lavell, Ayesha
    van der Straten, Karlijn
    Appelman, Brent
    Bontjer, Ilja
    Poniman, Meliawati
    Burger, Judith A.
    Oomen, Melissa
    Bouhuijs, Joey H.
    van Vught, Lonneke A.
    Slim, Marleen A.
    Schinkel, Michiel
    Wynberg, Elke
    van Willigen, Hugo D. G.
    Grobben, Marloes
    Tejjani, Khadija
    van Rijswijk, Jacqueline
    Snitselaar, Jonne L.
    Caniels, Tom G.
    Vlaar, Alexander P. J.
    Prins, Maria
    de Jong, Menno D.
    de Bree, Godelieve J.
    Sikkens, Jonne J.
    Bomers, Marije K.
    Sanders, Rogier W.
    PLOS MEDICINE, 2022, 19 (05)
  • [49] BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis
    Tomita, Yusuke
    Sato, Ryo
    Ikeda, Tokunori
    Sakagami, Takuro
    VACCINE, 2020, 38 (41) : 6352 - 6356
  • [50] Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells
    Fernando Garcia-Jimenez, Alvaro
    Caceres-Martell, Yaiza
    Fernandez-Soto, Daniel
    Martinez Fleta, Pedro
    Casasnovas, Jose M.
    Sanchez-Madrid, Francisco
    Rodriguez Frade, Jose Miguel
    Vales-Gomez, Mar
    Reyburn, Hugh T.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2022, 112 (02) : 339 - 346